Vertex (VRTX) Summer Orkambi Slowdown Impact Should Be Elimited by Q4 - Leerink

September 14, 2016 1:59 PM EDT
Get Alerts VRTX Hot Sheet
Price: $81.37 +0.57%

Rating Summary:
    24 Buy, 17 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade VRTX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Leerink Partners analyst Geoffrey Porges weighed in on Vertex (NASDAQ: VRTX) following comments from the CFO that "…when we look at Q3, one thing we are seeing in the US is a slowdown in refills in the July and August timeframe."

Porges notes slowdown was mentioned as unanticipated, but importantly "patients are [still] reinitiating or getting their refill later and we have been able to track patient to patient to see that. So it’s not discontinuations."

He also notes that the CFO reaffirmed guidance that Orkambi is experiencing 70%-80% persistence and compliance rates in the US.

Porges said the summer Okambi slowdown could impact 3Q US Orkambi sales by up to 15% and EPS by up to 50%, but the impact should be eliminated by 4Q.

The firm maintained an Outperform and price target of $113 on VRTX.

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $95.27 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Trader Talk

Add Your Comment